Customer Demand Communication and Project Design
Our process begins with in-depth consultations to understand your research objectives and tailor a bespoke VLP-based solution.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
In response to the evolving global health landscape, Creative Biolabs, a leading biotechnology company with decades of experience, proudly offers one-stop virus-like particle (VLP) vaccine-based anti-monkeypox drug discovery solutions. Our advanced technological platform offers comprehensive services for viral surface antigen screening, VLP production and assembly, and anti-monkeypox VLP vaccine efficacy evaluation, consistently yielding robust results.
Monkeypox virus (MPXV) is a double-stranded DNA virus belonging to the Orthopoxvirus genus within the Poxviridae family. Its genome is approximately 190 kilobase pairs in length, encoding around 190 proteins crucial for viral replication, immune evasion, and pathogenesis. The virus comprises a brick-shaped virion with a complex structure, including an outer envelope, a dumbbell-shaped core containing the genome, and lateral bodies. Infection typically occurs through direct contact with infected animals or humans, or contaminated materials, leading to a characteristic rash and systemic symptoms.
Fig.1 Virion protein sequencing for OPV.1.3
VLPs are sophisticated nanostructures formed by the self-assembly of viral structural proteins, mimicking the native conformation of the parent virus without containing any genetic material. This inherent lack of viral genome renders VLPs non-infectious, providing an exceptional safety profile. VLP vaccines have emerged as a highly promising platform due to their unique advantages:
Fig.2 Immune response activation by VLP vaccine.2,3
Creative Biolabs provides an end-to-end suite of services for VLP-based anti-monkeypox drug discovery and vaccine development. Leveraging our extensive expertise and advanced platforms, we guide clients through every stage, from initial antigen identification to preclinical validation, ensuring optimal outcomes for their projects.
We identify key MPXV capsid and surface proteins (e.g., A35R, B21R, M1R, L1R) and screen pathogen-specific antigens. Our team designs and engineers VLPs displaying optimized monkeypox antigens for maximal immunogenicity and specificity, utilizing advanced recombinant techniques across various VLP platforms.
Utilizing state-of-the-art bioreactor technologies and optimized purification strategies, we ensure the production of high-quality, high-purity VLPs suitable for research to preclinical batches.
Our analytical capabilities include electron microscopy (EM) for morphological assessment, dynamic light scattering (DLS) for size and polydispersity, SDS-PAGE and Western Blot for protein integrity, and mass spectrometry for antigen confirmation.
We develop and perform in vitro assays to assess antibody titers, neutralizing antibody activity against MPXV, and cellular immune responses (e.g., T-cell proliferation, cytokine secretion) elicited by VLP vaccine candidates.
We assist in identifying and incorporating optimal adjuvants to further enhance the immune response and protective potential of VLP vaccines.
We conduct in vivo studies to evaluate the protective efficacy of VLP vaccine candidates against MPXV challenge in appropriate animal models, providing crucial data for preclinical advancement.
Our support extends to comprehensive preclinical development, including toxicology studies and immunogenicity assessments in relevant animal models, guiding your VLP vaccine candidate towards successful clinical trials.
Our process begins with in-depth consultations to understand your research objectives and tailor a bespoke VLP-based solution.
Upon agreement, we formalize collaboration with a clear contract, outlining deliverables and timelines, then immediately launch your project.
Our experienced scientific team executes all experimental stages—from VLP design and production to characterization and immunogenicity testing—adhering to the highest scientific standards.
We perform rigorous data analysis, interpreting results and compiling comprehensive reports with clear insights and actionable conclusions.
Final results and materials are delivered promptly, with follow-up consultations for queries and ongoing scientific support.
Click the button to contact us for service details and a custom quote.
VLP vaccines hold immense promise in combating monkeypox beyond traditional prophylactic approaches. Their ability to elicit robust and broad immune responses makes them ideal for developing next-generation prophylactic vaccines, potentially offering superior protection and a safer profile compared to existing options. Furthermore, VLPs can serve as versatile platforms for diagnostic reagent development, aiding in rapid and accurate detection of MPXV infection. Their modular nature also allows for exploration in therapeutic applications, such as delivering immunomodulatory molecules or acting as antigen carriers for T-cell therapies, opening new avenues for both prevention and treatment strategies against monkeypox.
High Immunogenicity
Our VLP platforms are engineered to present monkeypox antigens in a highly ordered and repetitive manner, ensuring the induction of strong and durable humoral and cellular immune responses.
Unparalleled Safety
As VLPs lack viral genetic material, they are entirely non-infectious, providing a superior safety profile crucial for vaccine development and regulatory approval.
Scalable Production
Leveraging advanced expression systems and bioprocessing techniques, we ensure the efficient and scalable production of high-purity VLPs, meeting demands from research to preclinical stages.
Comprehensive Characterization
We provide in-depth physical, chemical, and biological characterization of VLPs, ensuring quality, consistency, and a thorough understanding of your vaccine candidate.
Expert Scientific Support
Our multidisciplinary team of virologists, immunologists, and protein engineers offers unparalleled scientific guidance and collaborative support throughout your entire project lifecycle.
Ensuring the high purity and quality of our VLP products is paramount at Creative Biolabs. We employ state-of-the-art bioreactor technologies for optimized expression and utilize advanced multi-step purification strategies, including chromatography and tangential flow filtration. Each batch undergoes rigorous quality control assessments, including electron microscopy, DLS, SDS-PAGE, and mass spectrometry, to confirm structural integrity, purity, and antigen presentation.
Absolutely. We offer comprehensive support for in vivo efficacy studies. We have established protocols and access to appropriate animal models for evaluating the protective potential of VLP vaccine candidates against monkeypox challenge. Our services include experimental design, execution, sample analysis, and interpretation of results to provide robust data for preclinical advancement.
VLP vaccines are designed to induce both robust humoral (antibody-mediated) and cellular (T-cell mediated) immune responses. The highly organized and repetitive antigen display on VLPs effectively stimulates B cells to produce high titers of neutralizing antibodies, while also activating antigen-presenting cells to prime potent T-cell responses, which are crucial for clearing viral infections.
Yes, we provide expert assistance in the selection and incorporation of optimal adjuvants. We understand that the choice of adjuvant can significantly impact the magnitude and quality of the immune response. Our team can recommend and test various adjuvants to enhance the immunogenicity of your VLP vaccine candidate, tailoring the formulation to your specific needs.
Scalability is a key consideration in our VLP production process. We utilize robust and adaptable expression systems, such as insect cell or yeast platforms, which are well-suited for large-scale biomanufacturing. Our process development team optimizes parameters to ensure consistent yield and quality from research-scale batches to larger preclinical production, laying the groundwork for future clinical and commercial scale-up.
Creative Biolabs is committed to long-term client relationships. After project completion and data delivery, we provide comprehensive follow-up support, including post-project consultations to discuss results, address any further questions, and offer guidance on next steps. We also remain available for future collaborations or additional service requests as your research progresses.
Creative Biolabs has been working in the field of therapeutic areas for years, and our scientists are fully confident in completing the most challenging projects. We provide the most comprehensive and robust one-stop virus-like particle vaccine-based anti-monkeypox drug discovery solutions and quality monkeypox products for our clients all over the world, please do not hesitate to contact us for more information if you have any demands.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.